Pasithea Therapeutics - Warrants (11/08/2026) Current Cash

As of the most recent data (March 2026), KTTAW shows a current cash of $50B. That compares with $5.3B in the prior-year period — up 843.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KTTAW's current cash is now $50B (was $5.3B) — a 843.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Pasithea Therapeutics - Warrants (11/08/2026) is outperforming or lagging.

Tracking KTTAW's current cash over time shows whether Pasithea Therapeutics - Warrants (11/08/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $50B That compares with $5.3B in the prior-year period — up 843.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Pasithea Therapeutics - Warrants (11/08/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $50B) with ownership activity and broader fundamentals.

Pasithea Therapeutics - Warrants (11/08/2026)'s current cash is $50B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.